Clinical Trial Update: A Study of Baricitinib in Participants With Rheumatoid Arthritis [Phase 4]

View source ↗

Summary

A Phase 4 study evaluating baricitinib in participants with rheumatoid arthritis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Olumiant (baricitinib) (baricitinib)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Rheumatoid Arthritis | Phase 4 | Status: COMPLETED